ProQR Reports FY 2025 Financial Highlights

Written by Emily J. Thompson, Senior Investment Analyst

Source: seekingalpha

Updated: Mar 12 2026

0mins

PRQR+7.28%

Should l Buy PRQR?

Source: seekingalpha

Earnings Per Share: ProQR reported a GAAP EPS of €0.40 for FY 2025, indicating a level of profitability despite financial challenges, reflecting ongoing investments in R&D and operations.
Cash Position: As of December 31, 2025, ProQR held approximately €92.4 million in cash and cash equivalents, a significant decrease from €149.4 million in 2024, indicating increased cash outflows in operations and necessitating a focus on future cash management strategies.
Operating Cash Usage: The net cash used in operating activities for FY 2025 was €52.8 million, up 44% from €36.4 million in 2024, highlighting pressure on operational expenditures that could impact future financial stability.
R&D Investment Growth: R&D costs for 2025 were €44.7 million, a 23% increase from €36.4 million last year, demonstrating the company's commitment to technological innovation and product development despite high expenditures.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy PRQR?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on PRQR

Wall Street analysts forecast PRQR stock price to rise

3 Analyst Rating

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 1.510

Low

5.00

Averages

8.67

High

12.00

Current: 1.510

Low

5.00

Averages

8.67

High

12.00

Oppenheimer

Kostas Biliouris

Outperform

initiated

2026-03-12

Reason

Oppenheimer

Kostas Biliouris

Price Target

AI Analysis

2026-03-12

initiated

Outperform

Reason

Oppenheimer analyst Kostas Biliouris assumed coverage of ProQR Therapeutics with an Outperform rating and $9 price target. The firm sees a lot to like for ProQR shares based on positive key opinion leader feedback ahead of the first half of 2026 target engagement data for AX-0810 in HV. Strong preclinical data support ProQR's RNA editing platform, and its KOL indicated that the company's unique approach could address the significant unmet need across 100K patients without available treatments in primary sclerosing cholangitis and bilary atresia.

Evercore ISI

Outperform

maintain

$4 -> $5

2025-07-11

Reason

Evercore ISI

Price Target

$4 -> $5

2025-07-11

maintain

Outperform

Reason

Evercore ISI raised the firm's price target on ProQR Therapeutics to $5 from $4 and keeps an Outperform rating on the shares. The firm adjusted price targets in Smid-cap biotechnology as part of a research note discussing 2026 stock ideas. There is a "notable lengthening" of time horizons among investors, which is a positive sign for the broader small cap biotech markets, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PRQR

Unlock Now

About PRQR

ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.